

## Study: ENGOT-ov78/ SALVOVAR

A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVage weekly dose-dense regimen in patients with poor prognostic OVARian cancers based on the tumor primary chemosensitivity and incomplete debulking surgery.

### MaNGO Sites

Prov	City	Site	Principal Investigator	Active **
AL	Alessandria	Ospedale SS Antonio e Biagio	Giulia Gallizzi	
BO	Bologna	Policlinico S. Orsola-Malpighi	Claudio Zamagni	
FI	Firenze	Ospedale Careggi	Maria Cristina Petrella	
LC	Lecco	Ospedale Manzoni	Federica Villa	
MI	Milano	Istituto Europeo di Oncologia	Gabriella Parma*	
VE	Mirano	Ospedale di Mirano	Alessandra Baldoni	

\* **MaNGO Principal Investigator**

\*\* **Activation ongoing**